Starpharma Holdings Ltd. (OTCMKTS:SPHRY – Get Free Report)’s share price fell 0.4% during trading on Monday . The stock traded as low as $4.25 and last traded at $4.68. Approximately 2,614 shares traded hands during trading, an increase of 333% from the average session volume of 603 shares. The stock had previously closed at $4.70.
Starpharma Stock Down 0.4%
The stock’s 50 day moving average is $4.92 and its two-hundred day moving average is $3.63.
About Starpharma
Starpharma is a clinical-stage biopharmaceutical company specializing in the development of dendrimer-based products across infectious disease, oncology and ophthalmology. Its proprietary dendrimer platform, DEP™ (Dendrimer Enhanced Products), enables precise molecular engineering to enhance drug delivery, targeting and safety profiles. The company’s lead product, VivaGel®, is a topical microbicide that has been approved in multiple markets for the treatment and prevention of bacterial vaginosis and is in clinical development for antiviral applications.
In addition to VivaGel, Starpharma is advancing pipeline candidates that leverage DEP technology to improve the performance of established and novel therapeutic agents.
Recommended Stories
- Five stocks we like better than Starpharma
- The AI Boom Has a Second Act—And It’s Playing Out in Optics
- Gold’s 2026 Rally Has Cracked—Is It Time to Buy the Pullback?
- 5 Tech Stocks to Buy on the July Pullback
- Is OpenAI’s IPO Delay a Warning for AI Investors?
Receive News & Ratings for Starpharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Starpharma and related companies with MarketBeat.com's FREE daily email newsletter.
